Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 14299.03%. This contributed to the annual value of -$43.2 million for FY2024, which is 2848.49% up from last year.
  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders amounted to $18.4 million in Q3 2025, which was up 24523.75% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders registered a high of $224.1 million during Q3 2022, and its lowest value of -$49.5 million during Q1 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders had a median value of -$12.7 million in 2024 and averaged $2.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 83367.27% in 2022, then tumbled by 15562.53% in 2023.
  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders (Quarter) stood at -$44.1 million in 2021, then skyrocketed by 300.84% to $88.5 million in 2022, then tumbled by 155.63% to -$49.2 million in 2023, then soared by 81.95% to -$8.9 million in 2024, then soared by 307.41% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $17.8 million for Q2 2025, and $8.5 million during Q1 2025.